Citations (120)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Zhaopeng Li, Deyong Bu, Xiaobin Wang, Lin Zhu, Daoyan Lei, Fengling Tang, Xianghua Sun, Cheng Chen, Xiang Ji & Song Bai. (2023) Chidamide and Oxaliplatin Synergistically Inhibit Colorectal Cancer Growth by Regulating the RPS27A-MDM2-P53 Axis. OncoTargets and Therapy 16, pages 703-721.
Read now
Read now
Wanjun Zhang, Junwei Niu, Yongcheng Ma, Xiawan Yang, Huixia Cao, Honggang Guo, Fengchang Bao, Ahmed Haw, Yuqing Chen & Kai Sun. (2020) The Synergistic Antitumor Activity of Chidamide in Combination with Bortezomib on Gastric Cancer. OncoTargets and Therapy 13, pages 3823-3837.
Read now
Read now
Qingzhu Jia, Ying Liu, Fangyou Yan, Qiang Wang & Peisheng Ma. (2017) Predicting the activity of hydroxamic acid analogues. Molecular Simulation 43:13-16, pages 1026-1033.
Read now
Read now
Jacob P. Laubach, Jesus F. San-Miguel, Vania Hungria, Jian Hou, Philippe Moreau, Sagar Lonial, Jae Hoon Lee, Hermann Einsele, Melissa Alsina & Paul G. Richardson. (2017) Deacetylase inhibitors: an advance in myeloma therapy?. Expert Review of Hematology 10:3, pages 229-237.
Read now
Read now
Nidhi Tandon, Vijay Ramakrishnan & Shaji K Kumar. (2016) Clinical use and applications of histone deacetylase inhibitors in multiple myeloma. Clinical Pharmacology: Advances and Applications 8, pages 35-44.
Read now
Read now
Paul G Richardson, R Donald Harvey, Jacob P Laubach, Philippe Moreau, Sagar Lonial & Jesús F San-Miguel. (2016) Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. Expert Review of Clinical Pharmacology 9:1, pages 35-48.
Read now
Read now
Paul G Richardson, Jacob P Laubach, Sagar Lonial, Philippe Moreau, Sung-Soo Yoon, Vânia TM Hungria, Meletios A Dimopoulos, Meral Beksac, Melissa Alsina & Jesús F San-Miguel. (2015) Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. Expert Review of Anticancer Therapy 15:7, pages 737-748.
Read now
Read now
Articles from other publishers (113)
Rong Sun, Zike Chen, Xuanhao Qu, Jie Zhang, Lehan Liu, Zhuheng Zhong, Weibing Zhang & Yihui Fan. (2024) Comprehensive Characterization of HATs and HDACs in Human Cancers Reveals Their Role in Immune Checkpoint Blockade. Critical Reviews in Eukaryotic Gene Expression 34:1, pages 41-53.
Crossref
Crossref
Fady Baselious, Dina Robaa & Wolfgang Sippl. (2023) Utilization of AlphaFold models for drug discovery: Feasibility and challenges. Histone deacetylase 11 as a case study. Computers in Biology and Medicine 167, pages 107700.
Crossref
Crossref
Anish K. Simhal, Kylee H. Maclachlan, Rena Elkin, Jiening Zhu, Larry Norton, Joseph O. Deasy, Jung Hun Oh, Saad Z. Usmani & Allen Tannenbaum. (2023) Gene interaction network analysis in multiple myeloma detects complex immune dysregulation associated with shorter survival. Blood Cancer Journal 13:1.
Crossref
Crossref
Yun Deng, Qian Cheng & Jing He. (2023) HDAC inhibitors: Promising agents for leukemia treatment. Biochemical and Biophysical Research Communications 680, pages 61-72.
Crossref
Crossref
Zechen Wang, Viswanathan Muthusamy, Daniel P. Petrylak & Karen S. Anderson. (2023) Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy. npj Precision Oncology 7:1.
Crossref
Crossref
Eleonora Russo, Carola Grondona, Chiara Brullo, Andrea Spallarossa, Carla Villa & Bruno Tasso. (2023) Indole Antitumor Agents in Nanotechnology Formulations: An Overview. Pharmaceutics 15:7, pages 1815.
Crossref
Crossref
Syed Abdulla Mehmood, Kantrol Kumar Sahu, Sounok Sengupta, Sangh Partap, Rajshekhar Karpoormath, Brajesh Kumar & Deepak Kumar. (2023) Recent advancement of HDAC inhibitors against breast cancer. Medical Oncology 40:7.
Crossref
Crossref
Angelica Ferro, Evangelia Pantazaka, Constantinos M. Athanassopoulos & Muriel Cuendet. (2023) Histone deacetylase‐based dual targeted inhibition in multiple myeloma. Medicinal Research Reviews.
Crossref
Crossref
Shamila D. Alipoor & Hong Chang. (2023) Exosomal miRNAs in the Tumor Microenvironment of Multiple Myeloma. Cells 12:7, pages 1030.
Crossref
Crossref
Takeshi Harada, Hiroto Ohguchi, Asuka Oda, Michiyasu Nakao, Jumpei Teramachi, Masahiro Hiasa, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Tomoko Maruhashi, Mamiko Takahashi, Shiro Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki, Shigeki Sano, Teru Hideshima & Masahiro Abe. (2023) Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase. Blood Advances 7:6, pages 1019-1032.
Crossref
Crossref
Weam Othman Elbezanti, Kishore B. Challagundla, Subash C. Jonnalagadda, Tulin Budak-Alpdogan & Manoj K. Pandey. (2023) Past, Present, and a Glance into the Future of Multiple Myeloma Treatment. Pharmaceuticals 16:3, pages 415.
Crossref
Crossref
Darren Pan, Tarek H. Mouhieddine, Ranjan Upadhyay, Nicole Casasanta, Angela Lee, Nicole Zubizarreta, Erin Moshier & Joshua Richter. (2023) Outcomes with panobinostat in heavily pretreated multiple myeloma patients. Seminars in Oncology 50:1-2, pages 40-48.
Crossref
Crossref
Hanley N. Abramson. (2023) Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma. International Journal of Molecular Sciences 24:3, pages 2645.
Crossref
Crossref
Chao Zhang, Yuna He, Xiuyun Sun, Wenyi Wei, Yanlong Liu & Yu Rao. (2023) PROTACs targeting epigenetic proteins. Acta Materia Medica 2:4.
Crossref
Crossref
Christophe Blanquart. 2023. Epigenetic Cancer Therapy. Epigenetic Cancer Therapy
507
538
.
Deirdra Venney, Graeme Greenfield, Patrick Preston, Adone Mohd-Sarip & Ken I. Mills. 2023. Epigenetic Cancer Therapy. Epigenetic Cancer Therapy
213
236
.
Madhumita Roy, Jaydip Biswas & Amitava DattaMadhumita Roy, Jaydip Biswas & Amitava Datta. 2023. Genetics and Epigenetics of Breast Cancer. Genetics and Epigenetics of Breast Cancer
59
87
.
Shicong Zhu, Cheng Xing, Guangsen Zhang, Hongling Peng & Zhihua Wang. (2022) CC1007, a small molecular compound, suppresses multiple myeloma via upregulation of Nur77. Bioorganic Chemistry 129, pages 106217.
Crossref
Crossref
Mai Nagasaka, Chiharu Miyajima, Hiromasa Aoki, Mineyoshi Aoyama, Daisuke Morishita, Yasumichi Inoue & Hidetoshi Hayashi. (2022) Insights into Regulators of p53 Acetylation. Cells 11:23, pages 3825.
Crossref
Crossref
Manav Gandhi, Viral Bakhai, Jash Trivedi, Adarsh Mishra, Fernando De Andrés, Adrián LLerena, Rohit Sharma & Sujit Nair. (2022) Current perspectives on interethnic variability in multiple myeloma: Single cell technology, population pharmacogenetics and molecular signal transduction. Translational Oncology 25, pages 101532.
Crossref
Crossref
Nor Hayati Ismail, Ali Mussa, Nur Atikah Zakaria, Mutaz Jamal Al-Khreisat, Muhamad Aidil Zahidin, Noor Nabila Ramli, Siti Nur Nabeela A’ifah Mohammad, Rosline Hassan, Noor Haslina Mohd Noor, Salfarina Iberahim, Zefarina Zulkafli, Shafini Mohamed Yusoff, Azlan Husin & Muhammad Farid Johan. (2022) The Role of Epigenetics in the Development and Progression of Multiple Myeloma. Biomedicines 10:11, pages 2767.
Crossref
Crossref
Soo Jin Kim, Suntae Kim, Yong June Choi, U Ji Kim & Keon Wook Kang. (2022) CKD-581 Downregulates Wnt/β-Catenin Pathway by DACT3 Induction in Hematologic Malignancy. Biomolecules & Therapeutics 30:5, pages 435-446.
Crossref
Crossref
Pedro A. Lazo. (2022) Targeting Histone Epigenetic Modifications and DNA Damage Responses in Synthetic Lethality Strategies in Cancer?. Cancers 14:16, pages 4050.
Crossref
Crossref
Jae Eun Lee & Mi-Young Kim. (2022) Cancer epigenetics: Past, present and future. Seminars in Cancer Biology 83, pages 4-14.
Crossref
Crossref
Margarita E. Neganova, Sergey G. Klochkov, Yulia R. Aleksandrova & Gjumrakch Aliev. (2022) Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress. Seminars in Cancer Biology 83, pages 452-471.
Crossref
Crossref
Yaiza Núñez‐Álvarez & Mònica Suelves. (2021) HDAC11: a multifaceted histone deacetylase with proficient fatty deacylase activity and its roles in physiological processes. The FEBS Journal 289:10, pages 2771-2792.
Crossref
Crossref
Thomas Webb, Conner Craigon & Alessio Ciulli. (2022) Targeting epigenetic modulators using PROTAC degraders: Current status and future perspective. Bioorganic & Medicinal Chemistry Letters 63, pages 128653.
Crossref
Crossref
Surabhi Suchanti, Bjorn J Stephen, Sonali Awasthi, Sudhir K Awasthi, Gyanendra Singh, Abhijeet Singh & Rajeev Mishra. (2022) Harnessing the role of epigenetic histone modification in targeting head and neck squamous cell carcinoma. Epigenomics 14:5, pages 279-293.
Crossref
Crossref
Geetha Shanmugam, Sudeshna Rakshit & Koustav Sarkar. (2022) HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases. Translational Oncology 16, pages 101312.
Crossref
Crossref
Zhenzhen Zhang, Xin Liu, Liyun Zhao, Yaru Zhou, Jianyou Shi, Weini Chen & Jinqi Li. (2022) A review on the treatment of multiple myeloma with small molecular agents in the past five years. European Journal of Medicinal Chemistry 229, pages 114053.
Crossref
Crossref
Xue-Song Xiang, Peng-Cheng Li, Wen-Quan Wang & Liang Liu. (2022) Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1877:1, pages 188676.
Crossref
Crossref
AGM Mostofa, Allison Distler, Mark B. Meads, Eva Sahakian, John J. Powers, Alexandra Achille, David Noyes, Gabriela Wright, Bin Fang, Victoria Izumi, John Koomen, Rupal Rampakrishnan, Tuan P. Nguyen, Gabriel De Avila, Ariosto S. Silva, Praneeth Sudalagunta, Rafael Renatino Canevarolo, Maria D. Coelho Siqueira Silva, Raghunandan Reddy Alugubelli, Hongyue A. Dai, Amit Kulkarni, William S. Dalton, Oliver A. Hampton, Eric A. Welsh, Jamie K. Teer, Alexandre Tungesvik, Kenneth L. Wright, Javier Pinilla-Ibarz, Eduardo M. Sotomayor, Kenneth H. Shain & Jason Brayer. (2021) Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma. JCI Insight 6:24.
Crossref
Crossref
Fatemeh Saadatpour, Fatemeh Mohammadipanah, Nazanin Zohourian & Mahshid Hodjat. (2022) Potential of nanoparticles and nanopolymers in treatment of age-associated diseases. Advances in Natural Sciences: Nanoscience and Nanotechnology 12:4, pages 045008.
Crossref
Crossref
Lisha Zheng, Ang Zhang, Jishan Liu, Min Liu & Yikun Zhang. (2021) HDAC1 promotes the migration of human myeloma cells via regulation of the lncRNA/Slug axis. International Journal of Molecular Medicine 49:1.
Crossref
Crossref
Mahdieh Mehrpouri, Atieh Pourbagheri-Sigaroodi & Davood Bashash. (2021) The contributory roles of histone deacetylases (HDACs) in hematopoiesis regulation and possibilities for pharmacologic interventions in hematologic malignancies. International Immunopharmacology 100, pages 108114.
Crossref
Crossref
Jesus G. Berdeja, Jacob P. Laubach, Joshua Richter, Steve Stricker, Andrew Spencer, Paul G. Richardson & Ajai Chari. (2021) Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 21:11, pages 752-765.
Crossref
Crossref
Antonia Kalushkova, Patrick Nylund, Alba Atienza Párraga, Andreas Lennartsson & Helena Jernberg-Wiklund. (2021) One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies. Epigenomes 5:4, pages 22.
Crossref
Crossref
Dina A Hafez, Islam A Hassanin, Mohamed Teleb, Sherine N Khattab, Kadria A Elkhodairy & Ahmed O Elzoghby. (2021) Recent advances in nanomedicine-based delivery of histone deacetylase inhibitors for cancer therapy. Nanomedicine 16:25, pages 2305-2325.
Crossref
Crossref
Suvir Singh, Kunal Jain, Rintu Sharma, Jagdeep Singh & Davinder Paul. (2021) Epigenetic Modifications in Myeloma: Focused Review of Current Data and Potential Therapeutic Applications. Indian Journal of Medical and Paediatric Oncology 42:05, pages 395-405.
Crossref
Crossref
Fa‐Qing Tian, Zi‐Ren Chen, Wei Zhu, Mei‐Qin Tang, Ju‐Heng Li, Xu‐Chang Zhang, Jian Jiang & Xiao‐Hui Cheng. (2021) Inhibition of hsa_circ_0003489 shifts balance from autophagy to apoptosis and sensitizes multiple myeloma cells to bortezomib via miR‐874‐3p/HDAC1 axis. The Journal of Gene Medicine 23:9.
Crossref
Crossref
Jacqueline Schütt, Theresa Nägler, Tino Schenk & Annamaria Brioli. (2021) Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic Modifications. Cancers 13:16, pages 4069.
Crossref
Crossref
Kenneth K.W. To & William C.S. Cho. (2021) Flavonoids Overcome Drug Resistance to Cancer Chemotherapy by Epigenetically Modulating Multiple Mechanisms. Current Cancer Drug Targets 21:4, pages 289-305.
Crossref
Crossref
Sridurga Mithraprabhu, Anna Kalff, Kate H. Gartlan, Ioanna Savvidou, Tiffany Khong, Malarmathy Ramachandran, Rachel E. Cooke, Kathryn Bowen, Geoffrey R. Hill, John Reynolds & Andrew Spencer. (2020) Phase II trial of single‐agent panobinostat consolidation improves responses after sub‐optimal transplant outcomes in multiple myeloma. British Journal of Haematology 193:1, pages 160-170.
Crossref
Crossref
Anaïs Schavgoulidze, Titouan Cazaubiel, Aurore Perrot, Hervé Avet-Loiseau & Jill Corre. (2021) Multiple Myeloma: Heterogeneous in Every Way. Cancers 13:6, pages 1285.
Crossref
Crossref
Yang Yang, Li-Juan Fu, Chun-Mei Chen & Mei-Wei Hu. (2021) Venetoclax in combination with chidamide and dexamethasone in relapsed/refractory primary plasma cell leukemia without t(11;14): A case report. World Journal of Clinical Cases 9:5, pages 1175-1183.
Crossref
Crossref
Jacob P. Laubach, Sascha A. Tuchman, Jacalyn M. Rosenblatt, Constantine S. Mitsiades, Kathleen Colson, Kelly Masone, Diane Warren, Robert A. Redd, Dena Grayson & Paul G. Richardson. (2021) Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma. Blood Cancer Journal 11:2.
Crossref
Crossref
Filomena de Nigris, Carlo Ruosi & Claudio Napoli. (2021) Clinical efficiency of epigenetic drugs therapy in bone malignancies. Bone 143, pages 115605.
Crossref
Crossref
Opelo Sefhore & Silvia CW Ling. 2021. Resistance to Targeted Therapies in Multiple Myeloma. Resistance to Targeted Therapies in Multiple Myeloma
83
104
.
Xi Yun Zhang, Deepa Rajagopalan, Tae-Hoon Chung, Lissa Hooi, Tan Boon Toh, Johann Shane Tian, Masturah Bte Mohd Abdul Rashid, Noor Rashidha Bte Meera Sahib, Mengjie Gu, Jhin Jieh Lim, Wilson Wang, Wee Joo Chng, Sudhakar Jha & Edward Kai-Hua Chow. (2020) Frequent upregulation of G9a promotes RelB-dependent proliferation and survival in multiple myeloma. Experimental Hematology & Oncology 9:1.
Crossref
Crossref
Xue-ting Hu, Wei Xing, Rong-sen Zhao, Yan Tan, Xiao-feng Wu, Luo-quan Ao, Zhan Li, Meng-wei Yao, Mu Yuan, Wei Guo, Shang-ze Li, Jian Yu, Xiang Ao & Xiang Xu. (2020) HDAC2 inhibits EMT-mediated cancer metastasis by downregulating the long noncoding RNA H19 in colorectal cancer. Journal of Experimental & Clinical Cancer Research 39:1.
Crossref
Crossref
Dorien Clarisse, Fritz Offner & Karolien De Bosscher. (2020) Latest perspectives on glucocorticoid-induced apoptosis and resistance in lymphoid malignancies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1874:2, pages 188430.
Crossref
Crossref
Shan-Shan Liu, Fei Wu, Yue-Mei Jin, Wei- Qin Chang & Tian-Min Xu. (2020) HDAC11: a rising star in epigenetics. Biomedicine & Pharmacotherapy 131, pages 110607.
Crossref
Crossref
Jingwen Li, Jing Zou, Xiaoyue Wan, Chunyan Sun, Zhangbo Chu & Yu Hu. (2020) Roles of noncoding RNAs in drug resistance in multiple myeloma. Journal of Cellular Physiology 235:11, pages 7681-7695.
Crossref
Crossref
Pedro Luiz Porfirio Xavier, Susanne Müller & Heidge Fukumasu. (2020) Epigenetic Mechanisms in Canine Cancer. Frontiers in Oncology 10.
Crossref
Crossref
Cinzia Caprio, Antonio Sacco, Viviana Giustini & Aldo M. Roccaro. (2020) Epigenetic Aberrations in Multiple Myeloma. Cancers 12:10, pages 2996.
Crossref
Crossref
Hirva Mamdani & Shadia I. Jalal. (2020) Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?. Frontiers in Cell and Developmental Biology 8.
Crossref
Crossref
Yifeng Sun, Zhao Xu, Jifeng Jiang, Tianhong Xu, Jiadai Xu & Peng Liu. (2020) High Expression of Succinate Dehydrogenase Subunit A Which Is Regulated by Histone Acetylation, Acts as a Good Prognostic Factor of Multiple Myeloma Patients. Frontiers in Oncology 10.
Crossref
Crossref
Marco Spreafico, Alicja M. Gruszka, Debora Valli, Mara Mazzola, Gianluca Deflorian, Arianna Quintè, Maria Grazia Totaro, Cristina Battaglia, Myriam Alcalay, Anna Marozzi & Anna Pistocchi. (2020) HDAC8: A Promising Therapeutic Target for Acute Myeloid Leukemia. Frontiers in Cell and Developmental Biology 8.
Crossref
Crossref
Jia Yang, Dengwen Li & Jun Zhou. (2020) Histone Deacetylase 6 as a Therapeutic Target in B cell-associated Hematological Malignancies. Frontiers in Pharmacology 11.
Crossref
Crossref
Linda Anna Michelle Kulka, Pia-Victoria Fangmann, Diana Panfilova & Heidi Olzscha. (2020) Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease. Frontiers in Cell and Developmental Biology 8.
Crossref
Crossref
Maria Cosenza, Monica Civallero, Luigi Marcheselli, Stefano Sacchi & Samantha Pozzi. (2020) Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination. Apoptosis 25:5-6, pages 370-387.
Crossref
Crossref
Mohammad Mosleh, Ava Safaroghli-Azar & Davood Bashash. (2020) Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: An emerging approach to overcome MSC-induced resistance. The International Journal of Biochemistry & Cell Biology 122, pages 105734.
Crossref
Crossref
Fehaid Alanazi, Faith A.A. Kwa, Genia Burchall & Denise E. Jackson. (2020) New generation drugs for treatment of multiple myeloma. Drug Discovery Today 25:2, pages 367-379.
Crossref
Crossref
Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Efstathios Kastritis, Maria Gavriatopoulou, Evangelos Terpos & Meletios Athanasios Dimopoulos. (2020) Efficacy of Panobinostat for the Treatment of Multiple Myeloma. Journal of Oncology 2020, pages 1-11.
Crossref
Crossref
Benigno C. Valdez, Yang Li, David Murray, Yan Liu, Yago Nieto, Qaiser Bashir, Muzaffar H. Qazilbash & Borje S. Andersson. (2020) Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells. Experimental Hematology 81, pages 32-41.
Crossref
Crossref
Nidhi Sharma, David T. Chen, Qiuhong Zhao, Nita Y. Williams, Ashley Rosko, Don M. Benson, Maria Chaudhry, Naresh Bumma, Abdullah Khan, Srinivas Devarakonda, Craig C. Hofmeister, Douglas Sborov & Yvonne A. Efebera. (2020) Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up. Biology of Blood and Marrow Transplantation 26:1, pages 44-49.
Crossref
Crossref
Mónica T. Fernandes, Hélder Almeida-Lousada & Pedro Castelo-Branco. 2020. Histone Modifications in Therapy. Histone Modifications in Therapy
1
15
.
Pierluigi Porcu, Gaurav Kumar, Nitin Chakravarti, Neeraj Arora, Anjali Mishra, Adam Binder, Adam Ertel & Paolo Fortina. 2020. Applied Genomics and Public Health. Applied Genomics and Public Health
53
72
.
A. Ganesan, Paola B. Arimondo, Marianne G. Rots, Carmen Jeronimo & María Berdasco. (2019) The timeline of epigenetic drug discovery: from reality to dreams. Clinical Epigenetics 11:1.
Crossref
Crossref
Katia Beider, Hanna Bitner, Valeria Voevoda-Dimenshtein, Evgenia Rosenberg, Yaarit Sirovsky, Hila Magen, Jonathan Canaani, Olga Ostrovsky, Noya Shilo, Avichai Shimoni, Michal Abraham, Lola Weiss, Michael Milyavsky, Amnon Peled & Arnon Nagler. (2019) The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators. Biochemical Pharmacology 168, pages 412-428.
Crossref
Crossref
Sridurga Mithraprabhu, Jay Hocking, Malarmathy Ramachandran, Kawa Choi, Daniela Klarica, Tiffany Khong, John Reynolds & Andrew Spencer. (2019) DNA-Repair Gene Mutations Are Highly Prevalent in Circulating Tumour DNA from Multiple Myeloma Patients. Cancers 11:7, pages 917.
Crossref
Crossref
Xiao Gao, Lijing Shen, Xiang Li & Jiaying Liu. (2019) Efficacy and toxicity of histone deacetylase inhibitors in relapsed/refractory multiple myeloma: Systematic review and meta‑analysis of clinical trials. Experimental and Therapeutic Medicine.
Crossref
Crossref
Sree H Pulugulla & Juraj Adamik. (2019) Epigenetics of Multiple Myeloma Bone Disease. Current Molecular Biology Reports 5:2, pages 86-96.
Crossref
Crossref
Xiang‑Gui Yuan, Yu‑Rong Huang, Teng Yu, Hua‑Wei Jiang, Yang Xu & Xiao‑Ying Zhao. (2019) Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase‑dependent manner. Oncology Letters.
Crossref
Crossref
Yoichi Imai, Mitsuhito Hirano, Masayuki Kobayashi, Muneyoshi Futami & Arinobu Tojo. (2019) HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action. Cancers 11:4, pages 475.
Crossref
Crossref
Subhayan Chattopadhyay, Hauke Thomsen, Pankaj Yadav, Miguel Inacio da Silva Filho, Niels Weinhold, Markus M. Nöthen, Per Hoffman, Uta Bertsch, Stefanie Huhn, Gareth J. Morgan, Hartmut Goldschmidt, Richard Houlston, Kari Hemminki & Asta Försti. (2019) Genome-wide interaction and pathway-based identification of key regulators in multiple myeloma. Communications Biology 2:1.
Crossref
Crossref
Zhiqiang Yu, Jun Zeng, Hui Liu, Tian Wang, Ziqi Yu & Jianyong Chen. (2019) Role of HDAC1 in the progression of gastric cancer and the correlation with lncRNAs. Oncology Letters.
Crossref
Crossref
Toby A. Eyre, Graham P. Collins, Avinash Gupta, Nicholas Coupe, Semira Sheikh, John Whittaker, Lai Mun Wang, Leticia Campo, Elizabeth Soilleux, Finn Tysoe, Richard Cousins, Nick La Thangue, Lisa K. Folkes, Michael R. L. Stratford, David Kerr & Mark R. Middleton. (2018) A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer. Cancer 125:1, pages 99-108.
Crossref
Crossref
Eva De Smedt, Hui Lui, Ken Maes, Kim De Veirman, Eline Menu, Karin Vanderkerken & Elke De Bruyne. (2018) The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response. Frontiers in Oncology 8.
Crossref
Crossref
Xuejiao Yin, Sui Huang, Ruiqi Zhu, Fengjuan Fan, Chunyan Sun & Yu Hu. (2018) Identification of long non-coding RNA competing interactions and biological pathways associated with prognosis in pediatric and adolescent cytogenetically normal acute myeloid leukemia. Cancer Cell International 18:1.
Crossref
Crossref
Hiroto Ohguchi, Teru Hideshima & Kenneth C. Anderson. (2018) The biological significance of histone modifiers in multiple myeloma: clinical applications. Blood Cancer Journal 8:9.
Crossref
Crossref
Maria Cosenza & Samantha Pozzi. (2018) The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease. International Journal of Molecular Sciences 19:8, pages 2337.
Crossref
Crossref
Mohammad Alzrigat, Alba Atienza Párraga & Helena Jernberg-Wiklund. (2018) Epigenetics in multiple myeloma: From mechanisms to therapy. Seminars in Cancer Biology 51, pages 101-115.
Crossref
Crossref
Vincent L. Hansen, Morton Coleman, Stephanie Elkins, Jeffrey P. Letzer, Moshe Yair Levy, Lasika Seneviratne, Jessica Rine, Marina White & Emil T. Kuriakose. (2018) An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma. Clinical Lymphoma Myeloma and Leukemia 18:6, pages 400-407.e1.
Crossref
Crossref
Alvaro del Real, Leyre Riancho-Zarrabeitia, Laura López-Delgado & José A. Riancho. (2018) Epigenetics of Skeletal Diseases. Current Osteoporosis Reports 16:3, pages 246-255.
Crossref
Crossref
Eleni-Dimitra Papanagnou, Evangelos Terpos, Efstathios Kastritis, Issidora S. Papassideri, Ourania E. Tsitsilonis, Meletios A. Dimopoulos & Ioannis P. Trougakos. (2018) Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent. Oncotarget 9:25, pages 17797-17809.
Crossref
Crossref
Ruosi Yao, Danyang Han, Xiaoyang Sun, Yu Xie, Qingyun Wu, Chunling Fu, Yao Yao, Hujun Li, Zhenyu Li & Kailin Xu. (2018) Scriptaid inhibits cell survival, cell cycle, and promotes apoptosis in multiple myeloma via epigenetic regulation of p21. Experimental Hematology 60, pages 63-72.
Crossref
Crossref
Amila Suraweera, Kenneth J. O’Byrne & Derek J. Richard. (2018) Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi. Frontiers in Oncology 8.
Crossref
Crossref
Amir Hosseini & Saverio Minucci. 2018. Epigenetics in Human Disease. Epigenetics in Human Disease
141
217
.
Inger S. Nijhof, Niels W. C. J. van de Donk, Sonja Zweegman & Henk M. Lokhorst. (2017) Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update. Drugs 78:1, pages 19-37.
Crossref
Crossref
Mark E. Issa, Farnaz Sedigheh Takhsha, Chandra Sekhar Chirumamilla, Claudina Perez-Novo, Wim Vanden Berghe & Muriel Cuendet. (2017) Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma. Clinical Epigenetics 9:1.
Crossref
Crossref
Nasrin Rastgoo, Jahangir Abdi, Jian Hou & Hong Chang. (2017) Role of epigenetics-microRNA axis in drug resistance of multiple myeloma. Journal of Hematology & Oncology 10:1.
Crossref
Crossref
J Long, W Y Fang, L Chang, W H Gao, Y Shen, M Y Jia, Y X Zhang, Y Wang, H B Dou, W J Zhang, J Zhu, A B Liang, J M Li & Jiong Hu. (2017) Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response. Leukemia 31:12, pages 2761-2770.
Crossref
Crossref
Charlotte Pawlyn & Gareth J. Morgan. (2017) Evolutionary biology of high-risk multiple myeloma. Nature Reviews Cancer 17:9, pages 543-556.
Crossref
Crossref
S Mithraprabhu, T Khong, M Ramachandran, A Chow, D Klarica, L Mai, S Walsh, D Broemeling, A Marziali, M Wiggin, J Hocking, A Kalff, B Durie & A Spencer. (2017) Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma. Leukemia 31:8, pages 1695-1705.
Crossref
Crossref
Daphné Dupéré-Richer & Jonathan D. Licht. (2017) Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma. Current Opinion in Hematology 24:4, pages 336-344.
Crossref
Crossref
Eckhard Klieser, Romana Urbas, Stefan St?ttner, Florian Primavesi, Tarkan J?ger, Adam Dinnewitzer, Christian Mayr, Tobias Kiesslich, Klaus Holzmann, Pietro Di Fazio, Daniel Neureiter & Stefan Swierczynski. (2017) Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome. Human Pathology 65, pages 41-52.
Crossref
Crossref
Hongyu Gao, Huihan Wang & Wei Yang. (2017) Identification of key genes and construction of microRNA?mRNA regulatory networks in multiple myeloma by integrated multiple GEO datasets using bioinformatics analysis. International Journal of Hematology 106:1, pages 99-107.
Crossref
Crossref
Dharshan Sivaraj, Michael M Green & Cristina Gasparetto. (2017) Panobinostat for the management of multiple myeloma. Future Oncology 13:6, pages 477-488.
Crossref
Crossref
Paul G. Richardson, Philippe Moreau, Jacob P. Laubach, Michelle E. Maglio, Sagar Lonial & Jesus San-Miguel. (2017) Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma. Pharmacological Research 117, pages 185-191.
Crossref
Crossref
Chunxiao Wu & Donglei Zhang. (2017) Identification of early-stage lung adenocarcinoma prognostic signatures based on statistical modeling. Cancer Biomarkers 18:2, pages 117-123.
Crossref
Crossref
Nagaraju Anreddy & Lori A. Hazlehurst. (2017) Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma. Journal of Cellular Biochemistry 118:1, pages 15-25.
Crossref
Crossref
Ariunzaya Bat-Erdene, Hirokazu Miki, Asuko Oda, Shingen Nakamura, Jumpei Teramachi, Ryota Amachi, Hirofumi Tenshin, Masahiro Hiasa, Masami Iwasa, Takeshi Harada, Shiro Fujii, Kimiko Sogabe, Kumiko Kagawa, Sumiko Yoshida, Itsuro Endo, Kenichi Aihara & Masahiro Abe. (2016) Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors. Oncotarget 7:48, pages 79064-79075.
Crossref
Crossref
Jesus F. San-Miguel, Hermann Einsele & Philippe Moreau. (2016) The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective. Advances in Therapy 33:11, pages 1896-1920.
Crossref
Crossref
Yixuan Li & Edward Seto. (2016) HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harbor Perspectives in Medicine 6:10, pages a026831.
Crossref
Crossref
Yusuke Furukawa & Jiro Kikuchi. (2016) Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma. International Journal of Hematology 104:3, pages 281-292.
Crossref
Crossref
Nicola Amodio, Maria Angelica Stamato, Anna Maria Gullà, Eugenio Morelli, Enrica Romeo, Lavinia Raimondi, Maria Rita Pitari, Ida Ferrandino, Gabriella Misso, Michele Caraglia, Ida Perrotta, Antonino Neri, Mariateresa Fulciniti, Christian Rolfo, Kenneth C. Anderson, Nikhil C. Munshi, Pierosandro Tagliaferri & Pierfrancesco Tassone. (2016) Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. Molecular Cancer Therapeutics 15:6, pages 1364-1375.
Crossref
Crossref
R F Cornell & A A Kassim. (2016) Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transplantation 51:4, pages 479-491.
Crossref
Crossref
Sarah L. Greig. (2016) Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma. Targeted Oncology 11:1, pages 107-114.
Crossref
Crossref
Seok-Mo Kim, Ki-Cheong Park, Jeong-Yong Jeon, Bup-Woo Kim, Hyeung-Kyoo Kim, Ho-Jin Chang, Seung-Hoon Choi, Cheong-Soo Park & Hang-Seok Chang. (2015) Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer. BMC Cancer 15:1.
Crossref
Crossref
Jacob P. Laubach, Philippe Moreau, Jesús F. San-Miguel & Paul G. Richardson. (2015) Panobinostat for the Treatment of Multiple Myeloma. Clinical Cancer Research 21:21, pages 4767-4773.
Crossref
Crossref
Karly P. Garnock-Jones. (2015) Panobinostat: First Global Approval. Drugs 75:6, pages 695-704.
Crossref
Crossref
Shicong Zhu, Cheng Xing, Guangsen Zhang, Hongling Peng & Zhihua Wang. (2022) The Small Molecular Compound CC1007 Suppresses Multiple Myeloma Via Upregulation of Nur77. SSRN Electronic Journal.
Crossref
Crossref